Latest News

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
07/24/15AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients
REDWOOD CITY, Calif., July 24, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive opinion for Zalviso™ (sufentanil sublingual tablets). The opinion, while not binding, recommends marketing authorization for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. Zalviso is an investigational dru... 
Printer Friendly Version
07/02/15Zalviso™ Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain
Results indicate Zalviso controlled moderate-to-severe acute pain following orthopedic surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., July 2, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that results from the IAP311 study have been published in Anesthesiology.  IAP... 
Printer Friendly Version
05/22/15AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June
REDWOOD CITY, Calif., May 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that interim chief executive officer Howie Rosen will be presenting at Jefferies 2015 Healthcare Conference and chief financial officer Tim Morris will be presenting at JMP Securities Life Science Conference. Details of the two pr... 
Printer Friendly Version
05/14/15AcelRx Awarded Contract from Department of Defense to Advance ARX-04
REDWOOD CITY, Calif., May 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced it has entered into Contract No. W81XWH-15-C-0046 worth up to $17.0 million, supported by the United States Army Medical Research and Materiel Command (USAMRMC) within the U.S. Department of Defense (DoD). The contract provides partial f... 
Printer Friendly Version
05/04/15AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results
REDWOOD CITY, Calif., May 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided a regulatory update on Zalviso and reported financial results for the three months ended March 31, 2015. Zalviso Regulatory Update On April 21, 2015, AcelRx submitted a request to the Division of Anesthesia, Analgesia, and Add... 
Printer Friendly Version
05/01/15AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May
REDWOOD CITY, Calif., May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer  will be participating in three upcoming investor events.  Details of the events are as follows: Mizuho Third Annual Healthcare Corporate Access Day Date: Tuesday, May 5 Location:  The Omni Ber... 
Printer Friendly Version
04/30/15AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015
REDWOOD CITY, Calif., April 30, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release First Quarter financial results after market close on Monday, May 4th, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 4th,... 
Printer Friendly Version
04/14/15AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting
Clinical Data from Two Different Development Programs Highlight Efficacy and Tolerability of Sublingual Sufentanil in Out-patient and In-patient Surgical Populations REDWOOD CITY, Calif., April 14, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting to be held April 15th to April 18th, 2015 at the Gaylord Opryland Resort and Convention... 
Printer Friendly Version
03/20/15AcelRx Appoints Howard B. Rosen as Interim CEO
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced the appointment of Howard B. Rosen as interim Chief Executive Officer of AcelRx, effective April 1, 2015. Mr. Ros... 
Printer Friendly Version
03/16/15AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04
SAP301 Trial to Study Sufentanil Sublingual Single-Dose Tablet for the Treatment of Moderate-to-Severe Acute Pain REDWOOD CITY, Calif., March 16, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. ARX-04 is a non-invasive, single-use 30 mcg sufenta... 
Printer Friendly Version
03/09/15AcelRx Provides Regulatory Update on Zalviso
REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided an update on the timing and potential content of the resubmission of the New Drug Application ("NDA") for Zalviso. AcelRx late last week received correspondence from the Food and Drug Administration ("FDA") stating that in addition to... 
Printer Friendly Version
03/09/15AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
REDWOOD CITY, Calif., March 9, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported financial results for the three and twelve months ended December 31, 2014.     Fourth Quarter 2014 Financial Results Net loss for the fourth quarter of 2014 was $13.8 million, or $0.32 basic and diluted net loss per share, compared... 
Printer Friendly Version
03/04/15AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015
REDWOOD CITY, Calif., March 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter and yearly 2014 financial results after market close on Monday, March 9th, 2015. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific... 
Printer Friendly Version
02/20/15AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events
REDWOOD CITY, Calif., Feb. 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E. Morris, chief financial officer will be presenting at RBC Capital Markets' Global Healthcare Conference and Cowen and Company's 35th Annual Healthcare Conference.  Details of the two presentations are as follows: ... 
Printer Friendly Version
02/04/15AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference
REDWOOD CITY, Calif., Feb. 4, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Timothy E Morris, Chief Financial Officer, will present a company overview and update at the 17th Annual BIO CEO & Investor Conference. Details of the presentation are as follows: BIO CEO & Investor Conference Dat... 
Printer Friendly Version

AcelRX

CONTACT